Paper Details

  1. Home
  2. Paper Details

Anakinra for rheumatoid arthritis.

Author: MertensMarty, SinghJasvinder A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Newer treatments called "biologics" that target specific inflammation-causing molecules in rheumatoid arthritis (RA) have significantly improved treatment options. Anakinra, a medication that blocks interleukin-1, is approved by the FDA for moderate to severe RA that hasn't responded to standard treatments.
Paper Details　
Original Abstract of the Article :
In the past decade, a novel class of therapies directed against specific cytokines implicated in the disease process of rheumatoid arthritis (RA), called the 'Biologics' have greatly improved and expanded treatment for RA. Anakinra is an interleukin-1 receptor antagonist that is currently FDA-approv...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/14651858.CD005121.pub3

データ提供：米国国立医学図書館（NLM）

Anakinra: A New Weapon in the Fight Against Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic inflammatory disease that can significantly impact quality of life. This study explores the role of anakinra, an interleukin-1 receptor antagonist, in the treatment of RA. Anakinra belongs to a new class of therapies called biologics, which target specific cytokines implicated in the disease process. The study states that anakinra is approved for moderate-to-severe RA that has not responded to traditional disease-modifying anti-rheumatic drugs (DMARDs).

Targeting Inflammation: A Promising Approach for RA

This study highlights the potential of anakinra as a therapeutic option for patients with RA who have not achieved satisfactory results with conventional treatments. By blocking interleukin-1, a key player in the inflammatory process, anakinra may help reduce inflammation and improve symptoms in RA patients.

Living with Rheumatoid Arthritis: Finding the Right Treatment

The camel understands the frustration and discomfort associated with chronic illnesses like rheumatoid arthritis. This study offers hope for patients with RA who have struggled to find effective treatments. Remember to work closely with your doctor to determine the best treatment approach for your individual needs.

Dr.Camel's Conclusion

This study offers a ray of hope for individuals battling rheumatoid arthritis. Anakinra, a targeted therapy that blocks a key inflammatory mediator, could potentially bring relief and improve quality of life for patients with RA. The camel is always eager to see new treatments emerge that can make a difference in the lives of those facing chronic illness.

Date :
  1. Date Completed 2009-03-19
  2. Date Revised 2018-12-21
Further Info :

Pubmed ID

19160248

DOI: Digital Object Identifier

10.1002/14651858.CD005121.pub3

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.